Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer [Seeking Alpha]
Actuate Therapeutics (NASDAQ: ACTU) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $20.00 price target on the stock.
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer [Yahoo! Finance]
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February